These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 25233346)

  • 1. Efficacy and safety of amphotericin B emulsion versus liposomal formulation in Indian patients with visceral leishmaniasis: a randomized, open-label study.
    Sundar S; Pandey K; Thakur CP; Jha TK; Das VN; Verma N; Lal CS; Verma D; Alam S; Das P
    PLoS Negl Trop Dis; 2014 Sep; 8(9):e3169. PubMed ID: 25233346
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of short-course multidrug treatment with standard therapy for visceral leishmaniasis in India: an open-label, non-inferiority, randomised controlled trial.
    Sundar S; Sinha PK; Rai M; Verma DK; Nawin K; Alam S; Chakravarty J; Vaillant M; Verma N; Pandey K; Kumari P; Lal CS; Arora R; Sharma B; Ellis S; Strub-Wourgaft N; Balasegaram M; Olliaro P; Das P; Modabber F
    Lancet; 2011 Feb; 377(9764):477-86. PubMed ID: 21255828
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase II, non-comparative randomised trial of two treatments involving liposomal amphotericin B and miltefosine for post-kala-azar dermal leishmaniasis in India and Bangladesh.
    Sundar S; Pandey K; Mondal D; Madhukar M; Kamal Topno R; Kumar A; Kumar V; Kumar Verma D; Chakravarty J; Chaubey R; Kumari P; Rashid MU; Maruf S; Ghosh P; Raja S; Rode J; den Boer M; Das P; Alvar J; Rijal S; Alves F
    PLoS Negl Trop Dis; 2024 Jun; 18(6):e0012242. PubMed ID: 38900786
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of available treatments for visceral leishmaniasis in Brazil: A multicenter, randomized, open label trial.
    Romero GAS; Costa DL; Costa CHN; de Almeida RP; de Melo EV; de Carvalho SFG; Rabello A; de Carvalho AL; Sousa AQ; Leite RD; Lima SS; Amaral TA; Alves FP; Rode J;
    PLoS Negl Trop Dis; 2017 Jun; 11(6):e0005706. PubMed ID: 28662034
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Single-dose liposomal amphotericin B for visceral leishmaniasis in India.
    Sundar S; Chakravarty J; Agarwal D; Rai M; Murray HW
    N Engl J Med; 2010 Feb; 362(6):504-12. PubMed ID: 20147716
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Amphotericin B colloidal dispersion for the treatment of Indian visceral leishmaniasis.
    Sundar S; Mehta H; Chhabra A; Singh V; Chauhan V; Desjeux P; Rai M
    Clin Infect Dis; 2006 Mar; 42(5):608-13. PubMed ID: 16447104
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and efficacy of short course combination regimens with AmBisome, miltefosine and paromomycin for the treatment of visceral leishmaniasis (VL) in Bangladesh.
    Rahman R; Goyal V; Haque R; Jamil K; Faiz A; Samad R; Ellis S; Balasegaram M; Boer MD; Rijal S; Strub-Wourgaft N; Alves F; Alvar J; Sharma B
    PLoS Negl Trop Dis; 2017 May; 11(5):e0005635. PubMed ID: 28558062
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Short-Course Treatment Regimen of Indian Visceral Leishmaniasis with an Indian Liposomal Amphotericin B Preparation (Fungisome™).
    Goswami RP; Goswami RP; Das S; Satpati A; Rahman M
    Am J Trop Med Hyg; 2016 Jan; 94(1):93-8. PubMed ID: 26526926
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of single-dose liposomal amphotericin B for visceral leishmaniasis in a rural public hospital in Bangladesh: a feasibility study.
    Mondal D; Alvar J; Hasnain MG; Hossain MS; Ghosh D; Huda MM; Nabi SG; Sundar S; Matlashewski G; Arana B
    Lancet Glob Health; 2014 Jan; 2(1):e51-7. PubMed ID: 25104636
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of Indian visceral leishmaniasis with single or daily infusions of low dose liposomal amphotericin B: randomised trial.
    Sundar S; Agrawal G; Rai M; Makharia MK; Murray HW
    BMJ; 2001 Aug; 323(7310):419-22. PubMed ID: 11520836
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New treatment approach in Indian visceral leishmaniasis: single-dose liposomal amphotericin B followed by short-course oral miltefosine.
    Sundar S; Rai M; Chakravarty J; Agarwal D; Agrawal N; Vaillant M; Olliaro P; Murray HW
    Clin Infect Dis; 2008 Oct; 47(8):1000-6. PubMed ID: 18781879
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and efficacy of paromomycin/miltefosine/liposomal amphotericin B combinations for the treatment of post-kala-azar dermal leishmaniasis in Sudan: A phase II, open label, randomized, parallel arm study.
    Younis BM; Mudawi Musa A; Monnerat S; Abdelrahim Saeed M; Awad Gasim Khalil E; Elbashir Ahmed A; Ahmed Ali M; Noureldin A; Muthoni Ouattara G; Nyakaya GM; Teshome S; Omollo T; Ochieng M; Egondi T; Mmbone M; Chu WY; Dorlo TPC; Zijlstra EE; Wasunna M; Alvar J; Alves F
    PLoS Negl Trop Dis; 2023 Nov; 17(11):e0011780. PubMed ID: 37988402
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and efficacy of high-dose infusions of a preformed amphotericin B fat emulsion for treatment of Indian visceral leishmaniasis.
    Sundar S; Singh A; Agarwal D; Rai M; Agrawal N; Chakravarty J
    Am J Trop Med Hyg; 2009 May; 80(5):700-3. PubMed ID: 19407109
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness of Single-Dose Liposomal Amphotericin B in Visceral Leishmaniasis in Bihar.
    Sundar S; Singh A; Agrawal N; Chakravarty J
    Am J Trop Med Hyg; 2019 Oct; 101(4):795-798. PubMed ID: 31436156
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessing the Efficacy and Safety of Liposomal Amphotericin B and Miltefosine in Combination for Treatment of Post Kala-Azar Dermal Leishmaniasis.
    Ramesh V; Dixit KK; Sharma N; Singh R; Salotra P
    J Infect Dis; 2020 Feb; 221(4):608-617. PubMed ID: 31854451
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination Therapy Against Indian Visceral Leishmaniasis with Liposomal Amphotericin B (Fungisome
    Goswami RP; Rahman M; Das S; Tripathi SK; Goswami RP
    Am J Trop Med Hyg; 2020 Jul; 103(1):308-314. PubMed ID: 32394874
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and efficacy of liposomal amphotericin B for treatment of complicated visceral leishmaniasis in patients without HIV, North-West Ethiopia.
    Tamiru A; Tigabu B; Yifru S; Diro E; Hailu A
    BMC Infect Dis; 2016 Oct; 16(1):548. PubMed ID: 27724891
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Amphotericin B treatment for Indian visceral leishmaniasis: conventional versus lipid formulations.
    Sundar S; Mehta H; Suresh AV; Singh SP; Rai M; Murray HW
    Clin Infect Dis; 2004 Feb; 38(3):377-83. PubMed ID: 14727208
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Injectable paromomycin for Visceral leishmaniasis in India.
    Sundar S; Jha TK; Thakur CP; Sinha PK; Bhattacharya SK
    N Engl J Med; 2007 Jun; 356(25):2571-81. PubMed ID: 17582067
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Amphotericin B for treatment of visceral leishmaniasis: systematic review and meta-analysis of prospective comparative clinical studies including dose-ranging studies.
    Rodrigo C; Weeratunga P; Fernando SD; Rajapakse S
    Clin Microbiol Infect; 2018 Jun; 24(6):591-598. PubMed ID: 29138100
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.